Related Experiment Videos
alpha 2 adrenergic agonists prevent MK-801 neurotoxicity
N B Farber1, J Foster, N L Duhan
1Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA.
Summary
Alpha 2 adrenergic agonists can prevent neurotoxic side effects caused by N-methyl-D-aspartate (NMDA) receptor antagonists. This finding suggests combining these agents may improve the safety of NMDA antagonists for neurotherapeutics.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- N-methyl-D-aspartate (NMDA) receptor antagonists are explored for neuroprotection, pain management, and preventing opiate tolerance.
- NMDA antagonists can induce severe side effects, including neurodegeneration and psychosis.
Purpose of the Study:
- To investigate mechanisms of NMDA antagonist-induced neuropathology.
- To identify methods for preventing or suppressing these adverse effects.
Main Methods:
- Investigated neuropathological changes in rat brains.
- Explored the effects of alpha 2 adrenergic agonists on NMDA antagonist neurotoxicity.
Main Results:
- Alpha 2 adrenergic agonists demonstrated the ability to prevent NMDA antagonist-induced neurotoxicity in rat models.
- This indicates a potential protective mechanism against NMDA antagonist side effects.
Conclusions:
- Co-administration of alpha 2 adrenergic agonists with NMDA antagonists may offer a strategy to mitigate adverse effects.
- This approach could enhance the therapeutic safety and utility of NMDA antagonists.